Journal article

Prioritizing therapeutic targets using patient-derived xenograft models

KA Lodhia, AM Hadley, P Haluska, CL Scott

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | ELSEVIER | Published : 2015

Abstract

Effective systemic treatment of cancer relies on the delivery of agents with optimal therapeutic potential. The molecular age of medicine has provided genomic tools that can identify a large number of potential therapeutic targets in individual patients, heralding the promise of personalized treatment. However, determining which potential targets actually drive tumor growth and should be prioritized for therapy is challenging. Indeed, reliable molecular matches of target and therapeutic agent have been stringently validated in the clinic for only a small number of targets. Patient-derived xenografts (PDXs) are tumor models developed in immunocompromised mice using tumor procured directly fro..

View full abstract

Grants

Awarded by National Health & Medical Research Council of Australia


Awarded by United States National Institute of Health


Awarded by Mayo Clinic SPORE in Ovarian Cancer


Awarded by Ovarian Cancer Research Fund


Awarded by NATIONAL CANCER INSTITUTE


Funding Acknowledgements

This work was supported by fellowships and grants from the National Health & Medical Research Council of Australia grant 1062702 (CLS) and scholarship 1076048 (AMH); the Cancer Council Victoria Sir Edward Dunlop Fellowship in Cancer Research (CLS); the Victorian Cancer Agency Clinical Fellowship (CLS); United States National Institute of Health Grants: R01 CA184502 (PH) and Mayo Clinic SPORE in Ovarian Cancer CA136393 (PH), Minnesota Partnership for Biotechnology and Medical Genomics (PH, KL) and Ovarian Cancer Research Fund OCRF258797 (PH, Kt); and Ginkgo, LLC (PH). This work was made possible through the Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS and the Australian Cancer Research Foundation.